All Title Author
Keywords Abstract

PLOS ONE  2014 

Discovery of Novel AKT Inhibitors with Enhanced Anti-Tumor Effects in Combination with the MEK Inhibitor

DOI: 10.1371/journal.pone.0100880

Full-Text   Cite this paper   Add to My Lib


Tumor cells upregulate many cell signaling pathways, with AKT being one of the key kinases to be activated in a variety of malignancies. GSK2110183 and GSK2141795 are orally bioavailable, potent inhibitors of the AKT kinases that have progressed to human clinical studies. Both compounds are selective, ATP-competitive inhibitors of AKT 1, 2 and 3. Cells treated with either compound show decreased phosphorylation of several substrates downstream of AKT. Both compounds have desirable pharmaceutical properties and daily oral dosing results in a sustained inhibition of AKT activity as well as inhibition of tumor growth in several mouse tumor models of various histologic origins. Improved kinase selectivity was associated with reduced effects on glucose homeostasis as compared to previously reported ATP-competitive AKT kinase inhibitors. In a diverse cell line proliferation screen, AKT inhibitors showed increased potency in cell lines with an activated AKT pathway (via PI3K/PTEN mutation or loss) while cell lines with activating mutations in the MAPK pathway (KRAS/BRAF) were less sensitive to AKT inhibition. Further investigation in mouse models of KRAS driven pancreatic cancer confirmed that combining the AKT inhibitor, GSK2141795 with a MEK inhibitor (GSK2110212; trametinib) resulted in an enhanced anti-tumor effect accompanied with greater reduction in phospho-S6 levels. Taken together these results support clinical evaluation of the AKT inhibitors in cancer, especially in combination with MEK inhibitor.


[1]  Yuan TL, Cantly LC (2008) PI3K pathway alterations in cancer: variations on a theme. Oncogene 27: 5497–510. doi: 10.1038/onc.2008.245
[2]  Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, et al. (1997) Characterization of a 3-phosoinositude-dependant protein kinase which phosphorylates and activates protein kinase B alpha. Curr Biol 7: 261–9. doi: 10.1016/s0960-9822(06)00122-9
[3]  Currie RA, Walker KS, Gray A, Deak M, Casamayor A, et al. (1999) Role of phosphatidylinositol 3, 4, 5- triphosphate in regulating the activity and localization of 3-phosphoinositide-dependant protein kinase-1. Biochem J 337: 575–83. doi: 10.1042/0264-6021:3370575
[4]  Majumder PK, Sellers WR (2005) Akt regulated pathways in prostate cancer. Oncogene 24: 7465–74. doi: 10.1038/sj.onc.1209096
[5]  Hresko RC, Mueckler M (2005) mTOR/Rictor is the Ser 473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem 280: 40406–16. doi: 10.1074/jbc.m508361200
[6]  Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, et al. (2006) Prolonged Rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22: 159–68. doi: 10.1016/j.molcel.2006.03.029
[7]  Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the Rictor-mTOR complex. Science 307: 1098–101. doi: 10.1126/science.1106148
[8]  Rodon J, Dienstmann R, Serra V, Tabernero J (2013) Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol 10: 143–153. doi: 10.1038/nrclinonc.2013.10
[9]  Lin J, Sampath D, Nannini MA, Lee BB, Degtyarev M, et al. (2012) Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models. Clin Cancer Res 19: 1760–72. doi: 10.1158/1078-0432.ccr-12-3072
[10]  Davies BR, Greenwood H, Dudley P, Crafter C, Yu DH, et al. (2012) Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther 11: 873–87. doi: 10.1158/1535-7163.mct-11-0824-t
[11]  Saleh M, Papadopoulos K, Arabnia A, Patnaik A, Stein RM, et al. (2013) First in human study with ARQ 092, a novel pan AKT-inhibitor: Results from the advanced solid tumor cohorts. Am Assoc Cancer Res Annual Meet LB-197.
[12]  Rhodes N, Heerding DA, Duckett DR, Eberwein DJ, Knick VB, et al. (2008) Characterization of an AKT kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res 68: 2366–74. doi: 10.1158/0008-5472.can-07-5783
[13]  Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, et al. (2011) First-in-human clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol 29: 4688–95. doi: 10.1200/jco.2011.35.5263
[14]  Gilmartin AG, Bleam MR, Groy A, Moss KG, Minthorn EA, et al. (2011) GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res 17: 989–1000. doi: 10.1158/1078-0432.ccr-10-2200
[15]  Han EK-H, Leverson JD, McGonigal T, Shah OJ, Wood KW, et al. (2007) Akt inhibitor A-443653 induced rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition. Oncogene 26: 5655–61. doi: 10.1038/sj.onc.1210343
[16]  Takaishi H, Konishi H, Matsuzaki H, Ono Y, Shirai Y, et al. (1999) Regulation of nuclear translocation of Forkhead transcription factor AFX by protein kinase B. PNAS 96: 11836–41. doi: 10.1073/pnas.96.21.11836
[17]  Sos M, Fischer S, Ullrich R, Peifer M, Heuckmann JM, et al. (2009) Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK- pathway inhibition in cancer. PNAS 106: 18351–56. doi: 10.1073/pnas.0907325106
[18]  Burris HA, Siu LL, Infante JR, Wheler JJ, Kurkjian C, et al. (2011) Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase I first-in human study. J Clin Oncol 29 (suppl): 2003.
[19]  Spencer A, Yoon S-S, Harrison SJ, Morris S, Smith D, et al. (2011) Novel AKT inhibitor GSK2110183 shows favorable safety, pharmacokinetics, and clinical activity in Multiple Myeloma. Preliminary results from a phase I first-time-in-human study. Proc 53rd Am Soc Hematol Annual Meet; Dec10-13; San Diego, CA Abstract 1856.
[20]  Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, et al. (2007) A transforming mutation in the pleckstrin homology domain of Akt 1 in cancer. Nature 448: 439–44. doi: 10.1038/nature05933
[21]  Davies MA, Sternke-Hale K, Tellez C, Calderone TL, Deng W, et al. (2008) A novel Akt 3 mutation in melanoma tumors and cell lines. Br J Cancer 99: 1265–8.
[22]  Shoji K, Oda K, Nakagawa S, Hosokawa S, Nagae G, et al. (2009) The oncogenic mutation in plekstrin homology domain of Akt 1 in endometrial carcinomas. Br J Cancer 101: 145–8.
[23]  Lindhurst MJ, Sapp JC, Teer JK, Johnston JJ, Finn EM, et al. (2011) A mosaic activating mutation in AKT1 associated with the Proteus Syndrome. New Eng J Med 365: 611–9. doi: 10.1056/nejmoa1104017
[24]  Hussain K, Challis B, Rocha N, Payne F, Minic M, et al. (2011) An activating mutation of AKT2 and human hypoglycemia. Science 334: 474. doi: 10.1126/science.1210878
[25]  Wu W-I, Voegtli WC, Sturgis HL, Dizon FP, Vigers GPA, et al. (2010) Crystal structure of human AKT1 with an allosteric inhibitor reveals a new mode of kinase inhibition. PLoS One 9: e12913. doi: 10.1371/journal.pone.0012913
[26]  Morgan MA, Dolp O, Reuter CWM (2001) Cell-cycle-dependant activation of mitogen-activated protein kinase kinase (MEK1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling. Neoplasia 97: 1823–34. doi: 10.1182/blood.v97.6.1823
[27]  Ricciardi MR, Scerpa MC, Bergamo P, Ciuffreda L, Petrucci MT, et al. (2012) Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for “vertical” and “lateral” combination studies. J Mol Med 90: 1133–44. doi: 10.1007/s00109-012-0886-z
[28]  Ebi H, Costa C, Faber AC, Nishtala M, Kotani H, et al. (2013) PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1. PNAS 52: 21124–9. doi: 10.1073/pnas.1314124110
[29]  Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, et al. (2008) Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118: 3065–3074. doi: 10.1172/jci34739
[30]  Serra V, Scaltriti M, Prudkin L, Eichhorn PJA, Ibrahim H, et al. (2011) PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene 30: 2547–2557. doi: 10.1038/onc.2010.626
[31]  Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, et al. (2011) AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19: 58–71. doi: 10.1016/j.ccr.2010.10.031
[32]  Faber AC, Li D, Song Y, Liang MC, Yeap BY, et al. (2009) Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci U S A 106: 19503–8. doi: 10.1073/pnas.0905056106
[33]  Turke AB, Song Y, Costa C, Cook R, Arteaga CL, et al. (2012) MEK inhibition leads to PI3K/AKT activation be relieving a negative feedback on ERBB receptors. Cancer Res 72: 1–10. doi: 10.1158/0008-5472.can-11-3747
[34]  Hoeflich KP, O'Brien C, Boyd Z, Cavet G, Guerrero S, et al. (2009) In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res 15: 4649–64. doi: 10.1158/1078-0432.ccr-09-0317
[35]  Mirzoeva OK, Das D, Heiser LM, Bhattacharya S, Siwak D, et al. (2009) Basal subtype andMAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res 69: 565–72. doi: 10.1158/0008-5472.can-08-3389
[36]  Yoon YK, Kim HP, Han SW, Hur HS, Oh do Y, et al. (2009) Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells. Mol Cancer Ther 8: 2526–36. doi: 10.1158/1535-7163.mct-09-0300
[37]  Elkabets M, Vora S, Juric D, Morse N, Mino-Kenudson M, et al. (2013) mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer. Sci. Transl. Med. 5, 196ra99.
[38]  Corcoran RB, Rothenberg SM, Hata AN, Faber AC, Piris A, et al. (2013) TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Sci. Transl. Med. 5, 196ra98.


comments powered by Disqus